Table 1.
Patient characteristics by VTE status
| Characteristic | VTE (N = 404) | No VTE (N = 1282) | Total (N =1686) | P value | |
|---|---|---|---|---|---|
| Age | 0.02* | ||||
| Median | 63.5 | 65 | 64.5 | ||
| Range | 23 – 90 | 18 – 93 | 18 – 93 | ||
| Sex – no. (%) | 0.054 | ||||
| Male | 226 (55.9) | 788 (61.5) | 1014 (60.1) | ||
| Female | 178 (44.1) | 494 (38.5) | 672 (39.9) | ||
| Race – no. (%) | 0.1 | ||||
| Asian | 3 (0.7) | 5 (0.4) | 8 (0.5) | ||
| African American | 46 (11.4) | 108 (8.4) | 154 (9.1) | ||
| Caucasian | 341 (84.5) | 1123 (87.6) | 1464 (86.9) | ||
| Multiracial / Other | 5 (1.2) | 21 (1.7) | 26 (1.5) | ||
| Unknown | 9 (2.2) | 25 (1.9) | 34 (2.0) | ||
| Stage – no. (%) | 0.03 | ||||
| Stage I - III | 28 (6.9) | 135 (10.5) | 163 (9.6) | ||
| Stage IV | 376 (93.1) | 1147 (89.5) | 1523 (90.4) | ||
| Number of IO drug – no. (%) | >0.99 | ||||
| >1 | 8 (24.2) | 25 (75.8) | 33 (2.0) | ||
| 1 | 396 (24.0) | 1257 (76.0) | 1653 (98.0) | ||
| Type of Immunotherapy – no. (%) | 0.58 | ||||
| Ipilimumab | 8 (2.0) | 40 (3.1) | 48 (2.8) | ||
| Nivolumab | 214 (53.0) | 655 (51.1) | 869 (51.5) | ||
| Pembrolizumab | 106 (26.2) | 350 (27.3) | 456 (27.1) | ||
| Atezolizumab | 40 (9.9) | 135 (10.6) | 175 (10.4) | ||
| Durvalumab | 5 (1.2) | 14 (1.1) | 19 (1.1) | ||
| Avelumab | 8 (2.0) | 12 (0.9) | 20 (1.2) | ||
| Nivolumab + ipilimumab | 23 (5.7) | 76 (5.9) | 99 (5.9) | ||
| Current status – no. (%) | |||||
| Alive | 153 (37.9) | 627 (48.9) | 780 (43.36) | ||
| Dead | 251 (62.1) | 655 (51.1) | 906 (53.74) |
*
p-value by Wilcoxon rank sum test